JEOL Ltd.
6951・Prime Market・Electric Appliances
Business
JEOL Ltd. (JEOL) is a precision instrument manufacturer founded in 1949, which has operated three segments: Scientific & Metrology Instruments, centered on electron microscopes, analytical instruments, and measurement/inspection equipment; Industrial Equipment, including electron beam lithography systems for semiconductor manufacturing; and Medical Equipment, which was transferred to Sysmex in April 2026. Its major customers include universities, research institutions, semiconductor manufacturers, and pharmaceutical companies, and it provides sales and services globally through 33 subsidiaries worldwide, including in the United States, Europe, and Asia. Consolidated net sales for FY2026 (ending March 2026) were ¥179,353 million.
Business Model
Leveraging proprietary electron optics and analytical technologies at its core, the company manufactures high-value-added products such as transmission electron microscopes and electron beam lithography systems, selling them directly to research institutions, semiconductor manufacturers, and other customers worldwide through its sales subsidiaries. In addition to product sales, revenue is also generated from maintenance, services, and the purchase and resale of peripheral equipment. Industrial Equipment boasts an outstanding operating margin of 40.2%, driving profitability for the group as a whole.
Company Strengths
Industrial Equipment achieved net sales of ¥48,131 million, segment profit of ¥19,363 million, and a profit margin of 40.2% in FY2026 (ending March 2026). Orders and sales of Spot-Beam Electron Beam Lithography Systems and Single-Beam Mask Writers have progressed steadily, forming a high entry barrier through niche technologies indispensable for the sophistication of semiconductor manufacturing processes.
The company has 33 consolidated subsidiaries in the US, Europe, Asia, and elsewhere, and has built up a track record in the electron microscope field for over 70 years since its founding in 1949. Order backlog for Scientific & Metrology Instruments remained solid at ¥53,058 million (105.7% year on year), with stable demand continuing from universities, research institutions, and semiconductor manufacturers.
Total R&D expenses in FY2026 (ending March 2026) amounted to ¥11,405 million, of which ¥7,632 million was allocated to Scientific & Metrology Instruments and ¥2,387 million to Industrial Equipment. Total capital expenditure reached ¥20,182 million, with ¥15,493 million invested in Scientific & Metrology Instruments alone. The consolidation of Japan Superconductor Technology Inc. as a subsidiary also strengthened the technological foundation related to NMR.
ENVALITH's Perspective
Performance Trend
Revenue achieved four consecutive years of growth from ¥138,408 million in FY2022 to ¥196,695 million in FY2025, but FY2026 turned to an 8.8% decline at ¥179,353 million. Operating profit also decreased 26.7% from ¥35,501 million to ¥26,017 million, with the operating profit margin declining from 18.0% to 14.5%. External factors compounded, including U.S. science and technology budget cuts, stagnation in the Chinese economy, and delayed demand recovery for the Multi-Beam Mask Writer. Meanwhile, with the prior period's valuation loss on investment securities (¥12,381 million) dropping off, net profit increased to ¥22,097 million (up 18.2% year on year). For FY2027 (ending March 2027), revenue is forecast at ¥164,000 million (down 8.6%) and operating profit at ¥26,500 million (up 1.9%), with a full-fledged recovery in revenue expected to take time.
Growth Strategy
Under "Evolving Growth 2.0," the company is concentrating investment in semiconductor and life science fields, targeting an operating margin of 20% and ROE of 15% or higher in FY2029 (ending March 2029)
As a 5-year plan covering FY2025-FY2029 (ending March 2030), the company is strengthening strategic investment in the semiconductor and life science fields. In FY2026 (ending March 2026), the increase in tangible and intangible fixed assets expanded significantly to ¥20,182 million (vs. ¥7,030 million in the previous period), and construction in progress also surged to ¥12,784 million (vs. ¥1,183 million in the previous period). Expansion of production and development capacity is underway.
The low-profitability Medical Equipment business (operating margin of 0.4%) was transferred to Sysmex effective April 1, 2026. This is a structural reform to concentrate management resources on the two businesses of Scientific & Metrology Instruments and Industrial Equipment, aiming to improve the profitability of the business portfolio. The transfer price is still being calculated, and the gain or loss on transfer has not yet been finalized.
Against the backdrop of higher performance and diversification of DFB lasers used in optical transceivers for AI data centers, demand is expected to increase for manufacturing processes including mass-production ramp-up. Orders and sales have trended steadily along with the Single-Beam Mask Writer, positioning this as a core growth driver for the Industrial Equipment segment.
With a basic policy of a target dividend payout ratio of 30%, the annual dividend for FY2026 (ending March 2026) was ¥132 (vs. ¥106 in the previous period), for a payout ratio of 30.5%. In addition, the company conducted share buybacks totaling ¥12,770 million. For FY2027 (ending March 2027), an annual dividend of ¥132 (payout ratio of 30.5%) is also forecast, reflecting a policy of pursuing improved capital efficiency alongside enhanced shareholder returns.
Last updated: July 19, 2026